CSIMarket


Sab Biotherapeutics Inc   (SABS)
Other Ticker:  
 


 

Sab Biotherapeutics Inc

SABS's Financial Statements and Analysis



Sab Biotherapeutics Inc narrowed third quarter of 2023 net loss per share of $-1.00 compare to net loss per share of $-1.60 recorded in the same quarter a year ago and improved compare to net loss per share of $-1.40 realized in previous quarter.


third quarter of 2023
Earnings Per Share Revenues
$ -1 $  1 Mill
$+0.60     $-2M     -64.69 %



Sab Biotherapeutics Inc 's Revenue fell by -64.69 % in third quarter of 2023 (Sep 30 2023) year on year, to $1 million and advanced by 1381.98 % sequentially.


Sab Biotherapeutics Inc is Expected to report next financial results on April 13, 2024.

More on SABS's Income Statement



Sab Biotherapeutics Inc 's in thethird quarter of 2023 recorded net loss of $-5.102 million, an improvement compare to net loss of $-7.076 million in III. Quarter a year ago.

Sequentially net loss narrowed from net loss of $-6.881 million realized in previous quarter.

More on SABS's Growth

Sab Biotherapeutics Inc Inventories
In Sep 30 2023 company's net cash and cash equivalents decreased by $-5 million, capital expenditures fell by -0.0785048.66%, to $0 millions compare to same quarter a year ago

More on SABS's Cash flow Statement


Sab Biotherapeutics Inc does not pay out common stock dividend.

In trailing twelve-month period Sab Biotherapeutics Inc payed $ -2.19 cash per share, on a free-cash flow basis .

Book value fell by -25.55 % sequentially to $2.91 per share, -19.92% of net loss per share in trailing twelve-month period were subtructed from shareholder value.
Tangible Book value fell to $ 2.91 per share from $ 3.91.

Company issued 0.20 million shares or 3.94 % in Sep 30 2023.


More on SABS's Dividends

 Market Capitalization (Millions) 22
 Shares Outstanding (Millions) 5
 Total Debt (Millions $) 1
 Revenue (TTM) (Millions $) 4
 Net Income (TTM) (Millions $) -27
 Cash Flow (TTM) (Millions $) -6
 Capital Exp. (TTM) (Millions $) 0
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Employees (TTM) $ -




Sab Biotherapeutics Inc does not pay out common stock dividend.

In trailing twelve-month period Sab Biotherapeutics Inc had negative $ -2.19 cash flow per share, on a free-cash flow basis .

Book value fell by -25.55 % sequentially to $2.91 per share, -19.92% of net loss per share in trailing twelve-month period were subtructed from shareholder value.
Tangible Book value fell to $ 2.91 per share from $ 3.91.

Company issued 0.20 million shares or 3.94 % in Sep 30 2023.


More on SABS's Balance Sheets

 Market Capitalization (Millions) 22
 Shares Outstanding (Millions) 5
 Total Debt (Millions $) 1
 Revenue (TTM) (Millions $) 4
 Net Income (TTM) (Millions $) -27
 Cash Flow (TTM) (Millions $) -6
 Capital Exp. (TTM) (Millions $) 0
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Employees (TTM) $ -
   


  News about Sab Biotherapeutics Inc Earnings

Sab Biotherapeutics Inc. Faces Crisis as Top-line Plummets by -64.695% in Q3 2023

Sab Biotherapeutic...

SABS Shocks Investors with Devastating 98.653% Revenue Plunge in Q2 2023

Shocking Figures: SABS Declares Disastrous Q2 2023 Results
In a surprising turn of events, Sab Biotherapeutics Inc (SABS) has recently announced their dismal financial results for the second quarter of 2023, leaving investors puzzled and concerned. The revenue for this period has plummeted dramatically by a staggering -98.653%, reaching a mere $0.09 million. This colossal decline can be directly attributed to a sharp drop in demand and unfavorable market conditions. Comparatively, during the same reporting season last year, the company generated $0.58 million in revenue, illustrating the severity of the decline.
Adding to the concerns, SABS' net loss per share has further widened to $-0.14, compared ...

Record Losses and Dismal ROI Fuel Investor Concerns

Investors beware, as Sab Biotherapeutics Inc is not showing any signs of turning its financial situation around anytime soon. The company recently disclosed their disastrous fiscal period, with record losses reported of $-27 million during the 12 months ending in the first quarter of 2023, resulting in a negative return on investment (ROI) of -75.57%. This is a cause for deep concern for investors as it indicates that the company has not been able to generate profits from its operations.
The company's position in the healthcare sector is also concerning, as there are 628 other companies that have a higher return on investment. ...


Date modified: 2024-01-10T05:56:45+00:00





Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com